TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) (“Reunion”), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will participate in the Cantor Neurology & Psychiatry Conference taking place on October 6-7…


Previous articleSilo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option
Next articleSilo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology